Faculty Opinions recommendation of Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial.

2013 ◽  
Author(s):  
Nancy Lin ◽  
Ines Vaz-Luis
Keyword(s):  
Breast Cancer ◽  
Early Stage ◽  
Her2 Positive ◽  
Phase 3 ◽  
Her2 Positive Breast Cancer ◽  
Randomised Controlled ◽  
Positive Breast Cancer

Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial

2013 ◽  
Vol 14 (1) ◽  
pp. 88-96 ◽  
Author(s):  
Paul E Goss ◽  
Ian E Smith ◽  
Joyce O'Shaughnessy ◽  
Bent Ejlertsen ◽  
Manfred Kaufmann ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Early Stage ◽  
Her2 Positive ◽  
Phase 3 ◽  
Her2 Positive Breast Cancer ◽  
Randomised Controlled ◽  
Positive Breast Cancer

scholarly journals Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials

2021 ◽  
Vol 22 (8) ◽  
pp. 1139-1150
Author(s):  
Rosie Bradley ◽  
Jeremy Braybrooke ◽  
Richard Gray ◽  
Robert Hills ◽  
Zulian Liu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Early Stage ◽  
Meta Analysis ◽  
Randomised Trials ◽  
Her2 Positive ◽  
Her2 Positive Breast Cancer ◽  
Positive Breast Cancer

Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial

2018 ◽  
Vol 19 (12) ◽  
pp. 1630-1640 ◽  
Author(s):  
Mette S van Ramshorst ◽  
Anna van der Voort ◽  
Erik D van Werkhoven ◽  
Ingrid A Mandjes ◽  
Inge Kemper ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Her2 Positive ◽  
Open Label ◽  
Phase 3 ◽  
Her2 Positive Breast Cancer ◽  
Positive Breast Cancer

scholarly journals Impact of timing of trastuzumab initiation on long-term outcome of patients with early-stage HER2-positive breast cancer: the “one thousand HER2 patients” project

2018 ◽  
Vol 119 (3) ◽  
pp. 374-380 ◽  
Author(s):  
Giuseppe Gullo ◽  
Naomi Walsh ◽  
David Fennelly ◽  
Reetesh Bose ◽  
Janice Walshe ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Early Stage ◽  
Her2 Positive ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Her2 Positive Breast Cancer ◽  
The One ◽  
Positive Breast Cancer

scholarly journals Adjuvant breast cancer: (neo)adjuvant therapy for HER2-positive breast cancer

2019 ◽  
Vol 12 (4) ◽  
pp. 312-314 ◽  
Author(s):  
Christoph Suppan ◽  
Marija Balic
Keyword(s):  
Breast Cancer ◽  
Adjuvant Therapy ◽  
Annual Meeting ◽  
Early Stage ◽  
Postoperative Treatment ◽  
Her2 Positive ◽  
Her2 Positive Breast Cancer ◽  
Adjuvant Breast Cancer ◽  
American Society ◽  
Positive Breast Cancer

Summary Early stage HER2-positive cancer outcomes have been substantially improved over the last two decades, but there is still some potential for improvement. Several studies on the preoperative/postoperative treatment of HER2-positive breast cancer were presented at the American Society of Clinical Oncology (ASCO) 2019 annual meeting.

Sign in / Sign up

Export Citation Format

Share Document